Terry-Ann Burrell - 31 Jan 2023 Form 4/A - Amendment Insider Report for Beam Therapeutics Inc. (BEAM)

Role
Chief Financial Officer
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol
BEAM
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
4/A - Amendment
Filing time
19 Apr 2023, 16:30:45 UTC
Date Of Original Report
31 Mar 2023
Previous filing
30 Jan 2023
Next filing
05 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Award $0 +40,000 $0.000000 40,000 31 Jan 2023 Common Stock 40,000 $43.45 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 31, 2023, the Reporting Person filed a Form 4 that reported the acquisition of a stock option. The Form 4 inadvertently reported the number of stock options acquired (and the number of shares of common stock underlying such stock options) as 20,000 when, as reported in this amendment, the correct number is 40,000.
F2 This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.